- Home
- STRW vs BDTX Comparison
STRW vs BDTX Comparison
Compare STRW & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STRW | BDTX |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.1M | 148.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | STRW | BDTX |
|---|---|---|
| Price | $13.25 | $2.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $12.72 | $10.60 |
| AVG Volume (30 Days) | 25.3K | ★ 931.3K |
| Earning Date | 02-26-2026 | 03-05-2026 |
| Dividend Yield | ★ 4.80% | N/A |
| EPS Growth | ★ 19.41 | N/A |
| EPS | ★ 0.61 | 0.38 |
| Revenue | ★ $145,392,000.00 | $70,000,000.00 |
| Revenue This Year | $35.42 | N/A |
| Revenue Next Year | $7.19 | N/A |
| P/E Ratio | $21.96 | ★ $7.07 |
| Revenue Growth | ★ 29.76 | N/A |
| 52 Week Low | $8.70 | $1.20 |
| 52 Week High | $14.00 | $4.94 |
Technical Indicators
Market Signals| Indicator | STRW | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.81 | 41.19 |
| Support Level | $13.11 | $2.56 |
| Resistance Level | $13.44 | $2.83 |
| Average True Range (ATR) | 0.32 | 0.14 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 47.12 | 40.43 |
Price Performance
Historical ComparisonAbout STRW Strawberry Fields REIT Inc.
Strawberry Fields REIT Inc is a self-managed and self-administered company that specializes in the acquisition, ownership and triple-net leasing of skilled nursing facilities and other post-acute healthcare properties.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.